NCT04724447View on ClinicalTrials.gov

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Major Depressive Disorder
Interventions
DRUG

Valganciclovir

2 x 450mg VGCV tablets

DRUG

Placebo

Placebo equivalent of 900mg/day VGCV

Trial Locations (1)

74136

RECRUITING

Laureate Institute for Brain Research, Tulsa

Sponsors
All Listed Sponsors
lead

Laureate Institute for Brain Research, Inc.

OTHER